Table 3. MV analyses of biomarkers for OS in 89 bmCRPC-patients on Enzalutamide-therapy.
| Variables | PFS | OS | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| ALP-bouncing | 0.10 | 0.25 | |||
| Yes | 1 (reference) | 1 (reference) | |||
| No | 0.5 (0.2–1.1) | 0.6 (0.2–1.4) | |||
| Enzalutamide before AA | 0.77 | 0.41 | |||
| Yes | 1 (reference) | 1 (reference) | |||
| No | 0.9 (0.4–1.8) | 0.7 (0.4–1.5) | |||
| Enzalutamide before chemotherapy | 0.02 | 1 | 0.03 | ||
| Yes | 1 (reference) | 1 (reference) | |||
| No | 0.5 (0.2–0.9) | 0.4 (0.2–0.9) | |||
| PSA-decline >50% | 0.36 | 0.28 | |||
| Yes | 1 (reference) | 1 (reference) | |||
| No | 0.7 (0.4–1.4) | 1.5 (0.7–2.9) | |||
| LDH normalized anytime | 0.94 | 0.09 | |||
| Yes | 1 (reference) | 1 (reference) | |||
| No | 0.9 (0.4–2.2) | 0.5 (0.2–1.1) (1.1–3.5) | |||
| ALP rising after 12 weeks | 0.22 | 0.99 | |||
| No | 1 (reference) | 1 (reference) | |||
| Yes | 1.6 (0.7–3.6) | 1.0 (0.4–2.3) | |||
| ALP elevated at baseline | 0.55 | 0.92 | |||
| No | 1 (reference) | 1 (reference) | |||
| Yes | 0.8 (0.4–1.7) | 1.0 (0.5–2.2) | |||
| LDH elevated at baseline | 0.35 | 0.57 | |||
| No | 1 (reference) | 1 (reference) | |||
| Yes | 1.4 (0.7–3.0) | 0.8 (0.3–1.9) | |||
MV, multivariate; OS, overall survival; bmCRPC, bone metastatic castration-resistant prostate cancer; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ALP, alkaline phosphatase; AA, abiraterone acetate; PSA, prostate-specific antigen; LDH, lactate dehydrogenase.